Table 3.
Incidence of ADEs and Other Variables in the Ketamine Infusion with PCA Bolus Group, Combined Hydromorphone and Ketamine PCA Group, and Combined Morphine and Ketamine PCA Group (N=315)
| Variable | Ketamine Infusion with PCA Bolus (n=68) | Hydromorphone/Ketamine PCA (n=203) | Morphine/Ketamine PCA (n=44) | Total (n=315) | P value | Q value |
|---|---|---|---|---|---|---|
| Any ADE | 16 (24%) | 77 (38%) | 28 (64%) | 121 (38%) | <0.01* | <0.01* |
| Psychological symptoms | 2 (3%) | 11 (5%) | 9 (21%) | 22 (7%) | <0.01* | 0.02* |
| Neurological symptoms | 1 (2%) | 6 (3%) | 3 (7%) | 10 (3%) | 0.3 | >0.9 |
| Nausea with or without emesis | 1 (2%) | 22 (11%) | 17 (39%) | 40 (13%) | <0.01* | <0.01* |
| New-onset tachycardia | 10 (15%) | 46 (23%) | 12 (27%) | 68 (22%) | 0.2 | >0.9 |
| PCA abruptly stopped | 5 (7%) | 9 (4%) | 5 (11%) | 19 (6%) | 0.2 | >0.9 |
| Rapid response | 0 (0%) | 2 (1%) | 0 (0%) | 2 (1%) | >0.9 | >0.9 |
| PCA duration (days) | 3 (2) | 2 (2) | 2 (1) | 2 (2) | 0.2 | >0.9 |
| Hospital stay (days) | 5 (3) | 6 (5) | 6 (7) | 6 (5) | >0.9 | >0.9 |
| Postoperative MEDD | 286 (223) | 847 (1257) | 353 (350) | 657 (1054) | <0.01* | <0.01* |
Note: *Statistical significance with p<0.05.